Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr Sells 1,023 Shares

Posted by Thomas Dobrow on Mar 18th, 2023

Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) CAO Patricia Carr sold 1,023 shares of the company’s stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $133.22, for a total value of $136,284.06. Following the transaction, the chief accounting officer now directly owns 6,286 shares of the company’s stock, valued at $837,420.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Patricia Carr also recently made the following trade(s):

On Sunday, March 5th, Patricia Carr sold 1,148 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $140.76, for a total value of $161,592.48.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded down $2.08 during trading hours on Friday, hitting $135.14. 694,471 shares of the stock were exchanged, compared to its average volume of 547,988. The company has a debt-to-equity ratio of 1.85, a quick ratio of 2.03 and a current ratio of 2.79. Jazz Pharmaceuticals plc has a 12-month low of $125.36 and a 12-month high of $169.98. The company has a market cap of $8.56 billion, a price-to-earnings ratio of -38.07, a price-to-earnings-growth ratio of 0.76 and a beta of 0.73. The stock’s 50-day moving average price is $148.49 and its two-hundred day moving average price is $147.39.

Analyst Ratings Changes

Several brokerages have recently weighed in on JAZZ. StockNews.com began coverage on Jazz Pharmaceuticals in a research note on Thursday. They set a “buy” rating for the company. Needham & Company LLC reduced their target price on Jazz Pharmaceuticals from $210.00 to $205.00 and set a “buy” rating for the company in a research note on Thursday, March 2nd. The Goldman Sachs Group upped their target price on Jazz Pharmaceuticals from $190.00 to $212.00 and gave the stock a “buy” rating in a research note on Friday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $204.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, March 6th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $204.27.

Institutional Trading of Jazz Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Park Avenue Securities LLC grew its holdings in Jazz Pharmaceuticals by 2.3% in the 4th quarter. Park Avenue Securities LLC now owns 3,100 shares of the specialty pharmaceutical company’s stock valued at $494,000 after buying an additional 70 shares in the last quarter. IFP Advisors Inc grew its holdings in Jazz Pharmaceuticals by 26.5% in the 4th quarter. IFP Advisors Inc now owns 358 shares of the specialty pharmaceutical company’s stock valued at $64,000 after buying an additional 75 shares in the last quarter. Captrust Financial Advisors grew its holdings in Jazz Pharmaceuticals by 2.4% in the 1st quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock valued at $577,000 after buying an additional 86 shares in the last quarter. First Republic Investment Management Inc. grew its holdings in Jazz Pharmaceuticals by 0.7% in the 4th quarter. First Republic Investment Management Inc. now owns 12,062 shares of the specialty pharmaceutical company’s stock valued at $1,922,000 after buying an additional 88 shares in the last quarter. Finally, Huntington National Bank grew its holdings in Jazz Pharmaceuticals by 37.9% in the 4th quarter. Huntington National Bank now owns 324 shares of the specialty pharmaceutical company’s stock valued at $52,000 after buying an additional 89 shares in the last quarter. 89.79% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.